Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses

• Published in: Cell Vol. 185; no. 6; pp. 995 - 1007.e18
• Main Authors: Milligan, Jacob C., Davis, Carl W., Yu, Xiaoying, Ilinykh, Philipp A., Huang, Kai, Halfmann, Peter J., Cross, Robert W., Borisevich, Viktoriya, Agans, Krystle N., Geisbert, Joan B., Chennareddy, Chakravarthy, Goff, Arthur J., Piper, Ashley E., Hui, Sean, Shaffer, Kelly C.L., Buck, Tierra, Heinrich, Megan L., Branco, Luis M., Crozier, Ian, Holbrook, Michael R., Kuhn, Jens H., Kawaoka, Yoshihiro, Glass, Pamela J., Bukreyev, Alexander, Geisbert, Thomas W., Worwa, Gabriella, Ahmed, Rafi, Saphire, Erica Ollmann
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 17.03.2022; Elsevier
• Subjects: Animals; Antibodies, Neutralizing; Antibodies, Viral; antibody binding sites; antibody therapeutic; BASIC BIOLOGICAL SCIENCES; Bundibugyo virus; cross reaction; cryo-EM; disease severity; Ebola virus; Ebolavirus; Epitopes; glycoproteins; Glycoproteins - chemistry; Hemorrhagic Fever, Ebola; medical countermeasure; memory; monoclonal antibodies; monoclonal antibody; nonhuman primate; Protein Subunits; Sudan; Sudan virus; viruses; Sudan; Ebola virus; Sudan virus; ebolavirus; medical countermeasure; Bundibugyo virus; nonhuman primate; monoclonal antibody; cryo-EM; antibody therapeutic

Several ebolaviruses cause outbreaks of severe disease. Vaccines and monoclonal antibody cocktails are available to treat Ebola virus (EBOV) infections, but not Sudan virus (SUDV) or other ebolaviruses. Current cocktails contain antibodies that cross-react with the secreted soluble glycoprotein (sGP...